A dosing and dosimetry study showed that Cotara, a monoclonal antibody attached to a radioisotope, allowed patients with glioblastoma multiforme, a type of brain cancer, to meet or surpass the expected six-month median survival period. The findings validate Cotara's "ability to specifically concentrate in and deliver a high radiation dose to brain tumors," said an official from Peregrine Pharmaceuticals, which developed the treatment.

Related Summaries